Strides Pharma Science Ltd reports Q2FY27 revenue of ₹1,429.7 crore, up 17.1% YoY
- EBITDA rose 8.4% YoY to ₹250.9 crore; margin was 17.6%, down 140 bps YoY.
- Reported net profit was ₹134.1 crore, up 2.0% YoY and down 19.0% QoQ.
- Operational PAT increased 11.5% YoY to ₹135.8 crore; Q2FY26 and H1FY26 comparisons exclude ₹18.5 crore of one-time finance income.